1. Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression;Altschuler;Med Hypotheses,2005
2. AstraZeneca Pharaceuticals I. D1448C00004. A multi-centre, double-blind, randomised, parallel group, placebo-controlled and active controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR™) as mono-therapy in the treatment of adult patients with major depressive disorder (Amber study).
3. AstraZeneca Pharaceuticals I. D1448C00005. A multicenter, double-blind, randomized-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR™) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (Amethyst study).
4. AstraZeneca Pharmaceuticals D1448C00003. A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR) as mono-therapy in the treatment of adult patients with major depressive disorder (Opal study).
5. AstraZeneca Pharmaceuticals Inc. http://www.astrazenecaclinicaltrials.com/.